These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34085090)

  • 1. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
    Park SJ; Kim JH; Joo I; Han JK
    Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
    Park SJ; Kim JH; Joo I; Lee KB; Han JK
    Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important Radiologic and Clinical Factors for Predicting Overall Survival in Pancreatic Adenocarcinoma Patients Who Underwent FOLFIRINOX.
    Park SJ; Kim JH; Choi SY; Joo I
    Pancreas; 2024 Aug; 53(7):e553-e559. PubMed ID: 38530942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion.
    Park SJ; Jang S; Han JK; Kim H; Kwon W; Jang JY; Lee KB; Kim H; Lee DH
    Eur Radiol; 2021 Sep; 31(9):6889-6897. PubMed ID: 33740095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113).
    Guggenberger KV; Bley TA; Held S; Keller R; Flemming S; Wiegering A; Germer CT; Kimmel B; Kunzmann V; Hartlapp I; Anger F
    Eur J Radiol; 2023 Jun; 163():110834. PubMed ID: 37080059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Court CM; Janssen QP; Tao AJ; D'Angelica MI; Drebin JA; Gonen M; O'Reilly EM; Jarnagin WR; Wei AC;
    J Am Coll Surg; 2022 Aug; 235(2):342-349. PubMed ID: 35839413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
    Choi YH; Lee SH; You MS; Shin BS; Paik WH; Ryu JK; Kim YT; Kwon W; Jang JY; Kim SW
    Gut Liver; 2021 Mar; 15(2):315-323. PubMed ID: 32235008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.